AVE9633 / Sanofi, AbbVie - LARVOL DELTA

CD33-Targeted Therapies: Beating the Disease or Beaten to Death? (PubMed, J Clin Pharmacol) - "Gemtuzumab ozogamicin was the first and only CD33-directed antibody-drug conjugate to be US Food and Drug Administration approved for AML...Promising new strategies include cellular therapy mechanisms and linker molecules. This is an exciting target that requires a considerable amount of precision to yield clinical benefit."

Journal • Review • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology